iStock-962614456_2.jpg

media center

November 24, 2020

Ghent, Belgium / Rotterdam, The Netherlands / Miami, FL, USA
Allero Therapeutics and Abbreos join forces to clinically develop COVID-19 program

Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive immune responses, today announced a clinical development agreement to treat medical conditions associated with potentially lethal amounts of pro-inflammatory cytokines and chemokines (“cytokine storm”). A first focus of the agreement is the treatment of patients likely to progress into COVID-19-associated acute respiratory distress syndrome (ARDS).

View full press release

October 10, 2020

Ventac Holding USA forms Abbreos, Inc. with an undisclosed shareholder to develop an oral patch to treat certain diseases associated with a cytokine storm.

March 8, 2021

Miami, Fl/Ft. Detrick, Fredrick MD

Abbreos was selected to participate in the U.S Military Health System’s Vendor Day on March 25, 2021.
Vendor Day is a cooperative venture by the military service medical logistics agencies, located on Fort Detrick in Frederick, MD. The event is intended to help the services' medical logistics agencies with strategic market analysis of products/technologies that may be applicable to the austere medical environments.
For more information see: https://health.mil/Military-Health-Topics/Combat-Support/Medical-Logistics/Vendor-Day